Business Context and Reporting Period
Company: Glaukos Corporation (GKOS)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Glaukos is an ophthalmic pharmaceutical and medical technology company focused on developing dropless therapies for glaucoma, corneal disorders, and retinal diseases. Key commercial platforms include the iStent family of micro-invasive glaucoma surgery (MIGS) devices, the iDose TR intracameral drug delivery implant, and the iLink bio-activated pharmaceuticals for corneal disorders.
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 Value | 2024 Value |
|---|---|---|
| Net Sales | $507.4 million | $383.5 million |
| Gross Profit | $282.8 million | $289.5 million |
| Gross Margin | 56% | 75% |
| Operating Expenses | $482.4 million | $411.8 million |
| Net Loss | $(187.7) million | $(146.4) million |
| Cash & Short-term Investments | $278.8 million | $318.9 million |
| Working Capital | $373.7 million | $374.7 million |
Debt & Liquidity: The company had no outstanding convertible senior notes as of December 31, 2025, having fully redeemed or exchanged them in 2024. Total lease liabilities were approximately $106.5 million. Management believes existing cash and investments are sufficient to fund operations for at least the next 12 months.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 32% to $507.4 million, driven primarily by a 50% increase in U.S. glaucoma sales (led by iDose TR volume) and an 18% increase in international glaucoma sales.
- Gross Margin Compression: Gross margin declined significantly from 75% to 56%. This was primarily due to a one-time $112.9 million impairment charge recorded in Cost of Sales related to the Photrexa developed technology intangible asset, following the FDA approval of the successor product, Epioxa.
- Operating Expenses: Total operating expenses rose 17% to $482.4 million. Selling, General, and Administrative (SG&A) expenses increased 27% due to higher compensation (including stock-based compensation) and commercial infrastructure growth. Research and Development (R&D) expenses increased 10% to $150.6 million.
- Acquisitions: In May 2025, the company acquired Mobius Therapeutics, LLC for $12.4 million (net of cash) to add the Mitosol product to its portfolio.
Guidance, Outlook, and Risks
Management Commentary & Outlook
- Product Launches: The company received FDA approval for Epioxa (incision-free keratoconus treatment) in October 2025 and plans a commercial launch in Q1 2026. It also received FDA approval for the re-administration of iDose TR in January 2026.
- Reimbursement: The company continues to work with Medicare Administrative Contractors (MACs) to streamline reimbursement for iDose TR. While 2026 Medicare facility fee rates for glaucoma products saw modest increases, physician fee rates for certain procedures were reduced.
- Capital Expenditures: Construction on a new 200,000 square foot R&D and manufacturing facility in Huntsville, Alabama, is expected to begin in 2026, with projected capital expenditures exceeding $80.0 million over the project's life.
Risks and Contingencies
- Legal Proceedings: Glaukos is engaged in litigation against SpyGlass Pharma, Inc. and a former executive regarding alleged trade secret theft. An injunction was granted in December 2025, and a trial is scheduled for October 2026.
- Regulatory & Reimbursement: Risks include potential changes in healthcare legislation, trade tariffs (though exposure is currently deemed limited), and the complexity of securing consistent reimbursement codes for new products like iDose TR and Epioxa.
- Profitability: The company has an accumulated deficit of $933.1 million and cannot assure sustained profitability or positive cash flow in the future.
Investor Verification Checklist
- Impairment Impact: Verify the long-term impact of the $112.9 million Photrexa impairment on future gross margins as the company transitions to Epioxa.
- iDose TR Reimbursement: Monitor the status of physician fee reimbursement rates set by the seven Medicare Administrative Contractors (MACs) for iDose TR procedures.
- Epioxa Commercialization: Track the commercial launch progress and market adoption of Epioxa in 2026 following its Q1 2026 launch target.
- Legal Outcome: Follow the SpyGlass Pharma litigation trial scheduled for October 2026 regarding trade secret misappropriation.
- Capital Allocation: Review the execution and cost management of the new Huntsville, Alabama facility construction starting in 2026.